Researchers performed a detailed multi-omics analysis after transplanting a genetically engineered pig kidney into a brain-dead human recipient and tracked immune and physiological signals over 61 days. Teams from NYU Grossman School of Medicine and collaborators reported antibody- and T cell–driven rejection mechanisms, and crucially they demonstrated reversal of rejection using a combination of FDA-approved immunomodulatory drugs. The Nature publications provide day-by-day molecular snapshots and identify targets and timelines for managing xenograft immune responses in future living-patient trials. Investigators say the data will inform trial design and immunosuppression strategies for pig-organ transplantation.